Chosa Oncology AB Stock: price and insider trades · Sweden
No insider purchase over the last 90 days. The latest, by Peter Buhl, was filed 17 Jul 2026.
Chosa Oncology AB: what insiders have been doing
Chosa Oncology AB has a thin disclosure history in our data (latest filing: 17 July 2026). New filings will appear here as soon as they are published. Source: insider filings from Finansinspektionen. Past trades are no guide to future returns.
Insider Decl.
1
Thresholds
n/a
Buy Volume
€26,503
1 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySalePeter Buhl1 buy
Financial data
as of FY 2025FY ended December 2025 · cache
SEK 0.54
Analyst consensus
Income statement
Gross profitSEK 4.6M
EBITDA-SEK 5.9M
Net income-SEK 5.6M0.0% margin
Valuation
P/Book2.5x
Beta-0.01
Balance sheet & cash
Market capSEK 49.7M
Free Cash Flow-SEK 8.6M
Profitability & ownership
ROE-37.7%
ROA-24.7%
% insiders13.3%
% institutions0.0%
Last declaration on 17 July 2026
Declarations1 total
- 377,074 shares@ SEK 0.78100.0% of flowTeckningsoptionFI:csv-49cbdddad58d90794eafCanonical exit: 12 Oct 2026 (T+90)
1 of 1 declaration
About Chosa Oncology AB
Chosa Oncology AB is a biotechnology company focused on developing innovative cancer treatments. It is listed on the XSTO exchange.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
